In silico modification of (1R, 2R, 3R, 5S)-(-)- Isopinocampheylamine as inhibitors of M2 proton channel in influenza a virus subtype H1N1, using the molecular docking approach

Trends in Bioinformatics

Volumn 5, Issue 2, 2012, Pages 25-46

  Tambunan, U S F ^a   Harganingtyas, R ^a   Parikesit, A A ^a  

^a UNIVERSITY OF INDONESIA   (Indonesia)

Author keywords

Influenza a virus H1N1; Inhibitor; M2 protein channel; Molecular docking

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; ISOPINOCAMPHEYLAMINE; PROTEIN M2; RIMANTADINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CHEMICAL MODIFICATION; COMPUTER MODEL; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; HYDROGEN BOND; INFLUENZA VIRUS A H1N1; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; TOXICITY TESTING;

EID: 84861433635     PISSN: 19947941     EISSN: 20772254     Source Type: Journal    
DOI: 10.3923/tb.2012.25.46     Document Type: Article

References (36)

1. Alsarf, A, O. Al-Sagarr, A. Albarrak, I.A.M. Ginawi, T.D. Hussein and M.E. Sweelam, 2010. Hail community acceptance of A/H1N1 vaccine. J. Med. Sci., 10: 162-168.
2. Amir, A., M.A. Siddiqui, N. Kapoor, A. Arya and H. Kumar, 2011. In silico molecular docking of influenza virus (PB2) protein to check the drug efficacy. Trends Bioinform., 4: 47-55.
3. Balannik, V., J. Wang, Y. Ohigashi, X. Jing and E. Magavern et al., 2009. Design and pharmacological characterization of inhibitors of amantadine: Resistant mutants of the M2 ion channel of influenza a virus. Biochemistry, 48: 11872-11882.
4. Beigel, J.H., J. Farrar, A.M. Han, F.G. Hayden and R. Hyer et al., 2005. Avian influenza A (H5N1) infection in humans. Writing committee of the world health organization (WHO) consultation on human Influenza A/H5. N. Engl. J. Med., 353: 1374-1385.
5. Betakova, T., 2007. M2 Protein-A proton channel of influenza a virus. Curr. Pharm. Des., 13: 3231-3235.
6. Cheng, P.K.C., T.W.C. Leung, E.C.M. Ho, P.C.K. Leung, A.Y.Y. Ng, M.Y.Y. Lai and W.W. Lim, 2009. Oseltamivir- and amantadine-resistant influenza viruses A (H1N1). Emerg. Infect. Dis., 15: 966-968.
7. Cook, I.T., T.S. Leyh, S.A. Kadlubar and C.N. Falany, 2009. Structural rearrangement of SULT2A1: Effect sondehydroepiandrosterone and raloxifene sulfation. Horm. Mol. Biol. Clin. Invest, 1:81-87.
8. De Clercq, E, 2006. Antiviral agents active against influenza A virus. Nat. Rev. Drug Discov, 5: 1015-1025.
9. De Jong, M.D, T.T. Thanh, T.H. Khanh, V.M. Hien and G.J.D. Smith et al, 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med, 353: 2667-2672.
10. Du, Q.S, R.B. Huang, S.Q. Wang and K.C. Chou, 2010. Designing inhibitors of M2 protein channel against H1N1 swine influenza virus. PLoS one, Vol. 5, 10.1371/journal.pone.0009388
11. Egan, W.J, K.M. Jr. Merz and J.J. Baldwin, 2000. Prediction of drug absorption using multivariate statistic. J. Med. Chem, 43: 3867-3877.
12. Feher, M. and C.I. Williams, 2009. Effect of input differences on the results of docking calculations. J. Chem. Inform. Model, 49: 1704-1714.
13. Gonzalez-Diaz, H, F. Prado-Prado, L.G. Perez-Montoto, A. Duardo-Sanchez and A. Lopez-Diaz, 2009. QSAR models for proteins of parasitic organisms, plants and human guests: Theory, applications, legal protection, taxes and regulatory issues. Curr. Proteomics, 6: 214-227.
14. Halgren, T.A, 1999. MMFF VI. MMFF94s option for energy minimization studies. J. Comput. Chem, 20: 720-729.
15. Hu, W, S. Zeng, C. Li, Y. Jie, Z. Li and L. Chen, 2010. Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library. J. Med. Chem, 53:3831-3834.
16. Karim, S.A.A. and R. Razali, 2011. A proposed mathematical model of influenza A, H1N1 for Malaysia. J. Applied Sci, 11: 1457-1460.
17. Kitchen, D.B, H. Decornez, J.R. Furr and J. Bajorath, 2004. Docking and scoring in virtual screening for drug discovery: Methods and applications. Nat. Rev. Drug Discovery, 3: 935-949.
18. Lakshmi, P.T.V, S. Radhika and A. Annamalai, 2011. Molecular docking analysis of phyto-ligands with multi drug resistant P-lactamases of Staphylococcus aureus. Trends Bioinform, 4: 23-34.
19. Lehninger, A. and D.L. Nelson, 2005. Principles of Biochemistry. Wh Freeman, USA.
20. Lew, W, X. Chen and C.U. Kim, 2000. Discovery and development of GS 4104 (oseltamivir) an orally active influenza neuraminidase inhibitor. Curr. Med. Chem, 7: 663-672.
21. Mazur, P, T. Magdziarz, A. Bak, Z. Chilmonczyk and T. Kasprzycka-Guttman et al., 2010. Does molecular docking reveal alternative chemopreventive mechanism of activation of oxidoreductase by sulforaphane isothiocyanates?. J. Mol. Model, 16: 1205-1212.
22. Nurbaiti, S, H. Nagao, H. Saito, R. Hertadi, M.A. Martoprawiro and Akhmaloka, 2010. Domain motions of Klenow-like DNA polymerase I ITB-1 in the absence of substrate. Int. J. Integr. Biol, 9: 104-110.
23. Nylander, E, 2007. DockControl: A new integrated software for design of experiments and molecular docking: Application to HIV-protease inhibitors. MCS Thesis, Umea University, Department of Computer Science, Sweden.
24. Rungrotmongkol, T, P. Intharathep, M. Malaisree, N. Nunthaboot and N. Kaiyawet et al., 2009. Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus. Biochem. Biophys. Res. Commun, 385: 390-394.
25. Sar, T.T, P.T. Aernan and R.S. Houmsou, 2010. H1N1 influenza epidemic: Public health implications for Nigeria. Int. J. Virol, 6: 1-6.
26. Singh, H, S.S. Maria and M. Agarwal, 2007. Docking studies of Tau protein. Int. J. Comput. Sci, 33: 1-7.
27. Sohail, M.N, F. Rasul, A. Karim, U. Kanwal and I.H. Attitalla, 2011. Plant as a source of natural antiviral agents. Asian J. Anim. Vet. Adv., 6: 1125-1152.
28. Sur, S, G. Sen, S. Thakur, A.K. Bothra and A. Sen, 2009. In silico analysis of evolution in swine flu viral genomes through re-assortment by promulgation and mutation. Biotechnology, 8: 434-441.
29. Tambunan, U.S.F. and E.K. Wulandari, 2010. Identification of a better Homo sapiens class II HDAC inhibitor through binding energy calculations and descriptor analysis. Bio Med. Cent. Bioinform., Vol. 11, 10.1186/1471-2105-11-S7-S16.
30. Tambunan, U.S.F., Fadilah and Parikesit A.A., 2010. Bioactive compounds screening from zinglberaceae family as influenza a/swine flu virus neuraminidase inhibitor through docking approach. Online J. Biol. Sci., 10: 151-156.
31. Tambunan, U.S.F., O. Hikmawan and T.A. Tockary, 2008. In silico mutation study of haemagglutinin and neuraminidase on Banten province strain influenza a H5N1 virus. Trends Biomform, 1: 18-24.
32. Teodoro, M.L., G.n. Phillips and L.E. Kavraki, 2001. Molecular docking: A problem with thousands of degrees of freedom. Proceedings of the IEEE International Conference on Robotics and Automation, ICRA2001, May 21-26, 2001, Seoul, Korea,.
33. Veber, D.F, S.R. Johnson, H.Y. Cheng, B.R. Smith, K.W. Ward and K.D. Kopple, 2002. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem., 45: 2615-2623.
34. Webby, R.J. and R.G. Webster, 2001. Emergence of influenza A viruses. Philos. Trans. R. Soc. Lond B Biol. Sci., 356: 1817-1828.
35. Yahyapour, Y., R. Hamkar, A. Moradi, M. Mahmoudi, Z. Nourozbabaei, Z. Saadatmand and T.M. Azad, 2007. Isolation and typing of the influenza viruses in the Caspian littoral of Iran. J. Med. Sci, 7: 307-310.
36. Zhao, X, L. Chufang and H. Wenhui, 2011. Discovery of highly potent agents against influenza A virus. Eur. J. Med. Chem, 46: 52-57.